Presentation is loading. Please wait.

Presentation is loading. Please wait.

MULTICENTER RANDOMIZED CLINICAL TRIAL OF FSGS IN CHILDREN AND YOUNG ADULTS J Gassman, R Fine, A Friedman, D Gipson, T Greene, R Hogg, F Kaskel, M Moxey-Mims,

Similar presentations


Presentation on theme: "MULTICENTER RANDOMIZED CLINICAL TRIAL OF FSGS IN CHILDREN AND YOUNG ADULTS J Gassman, R Fine, A Friedman, D Gipson, T Greene, R Hogg, F Kaskel, M Moxey-Mims,"— Presentation transcript:

1 MULTICENTER RANDOMIZED CLINICAL TRIAL OF FSGS IN CHILDREN AND YOUNG ADULTS J Gassman, R Fine, A Friedman, D Gipson, T Greene, R Hogg, F Kaskel, M Moxey-Mims, M Radeva, N Siegel*, H Trachtman, S Watkins NIH NIDDK, Bethesda MD *deceased

2 Objectives Randomized trial to compare 2 therapeutic interventions for patients 2 – 40 yrs of age with steroid resistant FSGS Facilitate the investigation of complex pathobiology of FSGS Target sample size is 207 randomized patients to achieve 80% power to detect 17.9% absolute difference in remission rate

3 Outcomes Primary Outcome Attainment of partial or complete remission (6-level ordinal scale) Main Secondary Outcome No relapse after withdrawal of immunosuppressive agents Secondary Outcomes Treatment failures Change in eGFR Side effects Quality of life Biological materials

4 The primary outcome is defined as achievement of remission from proteinuria during the first 52 weeks after randomization *Complete remission: Decline in UP/C to no > than 0.2 *Partial remission: 50% or > decline to a level between 0.2 and 2.0 * Mean of 2 baseline measurements of first morning urine Primary Outcome Measures

5 Definition of Primary Outcome at 52 Weeks for Participants Achieving a Partial or Complete Remission at 26 Weeks Remission Category Sustained complete remission Limited complete remission Partial remission No remission Level1234 Definition Complete remission throughout weeks 26-52 Complete remission at W52 but Up/c > 0.2 between weeks 26 and 52 Partial remission at W52 No remission at W52

6 Main Secondary Outcome Measures 5-level ordinal categorical outcome based on the participant’s level of proteinuria during the period from W52 through W78 following withdrawal of CSA or MMF/Pulse steroids Participants remain on ACEi / ARB

7 Definition of Main Secondary Outcome at Week 78 for Participants with a Primary Outcome Level of at least 3 Remission Category Full persistence of complete remission Limited persistence of complete remission Partial remissionNo remission LevelABCD Definition Complete remission throughout weeks 52-78 Complete remission at week 78, but Up/c between 0.2 and 2.0 between weeks 52 and 78 Partial remission at week 78, and partial or complete remission between weeks 52 and 78 Failure to maintain at least a partial remission after week 52 Note: Participants who were assigned to levels 4, 5, or 6 for the primary outcome at the 26 and/or 52 week assessment will be assigned to level E for the main secondary outcome.


Download ppt "MULTICENTER RANDOMIZED CLINICAL TRIAL OF FSGS IN CHILDREN AND YOUNG ADULTS J Gassman, R Fine, A Friedman, D Gipson, T Greene, R Hogg, F Kaskel, M Moxey-Mims,"

Similar presentations


Ads by Google